Suppr超能文献

关注脂蛋白(a)及其相关心血管风险:从科学证据到临床实践。

Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice.

机构信息

Clinical Division of Endocrinology and Metabolism - Department of Medicine III - Medical University of Vienna, Universitätsring 1, 1010, Wien, Austria.

Department of Molecular Medicine, Lipid Clinic and Atherosclerosis Prevention Centre -"Sapienza" University of Rome, Extracorporeal Therapeutic Techniques Unit, Regional Centre for Rare Diseases, Immunohematology and Transfusion Medicine, "Umberto I" Hospital, Rome, Italy.

出版信息

Curr Atheroscler Rep. 2019 Jul 27;21(10):37. doi: 10.1007/s11883-019-0803-9.

Abstract

PURPOSE OF REVIEW

A considerable body of data from genetic and epidemiological studies strongly support a causal relationship between high lipoprotein(a) [Lp(a)] levels, and the development of atherosclerosis and cardiovascular disease. This relationship is continuous, unrelated to Lp(a) threshold, and independent of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol levels. Unfortunately, the mechanism(s) through which Lp(a) promotes atherosclerosis are not clarified yet. Suggested hypotheses include: an increased Lp(a)-associated cholesterol entrapment in the arterial intima followed by inflammatory cell recruitment, abnormal upload of proinflammatory oxidized phospholipids, impaired fibrinolysis by inhibition of plasminogen activation, and enhanced coagulation, through inhibition of the tissue factor pathway inhibitor. This review is aimed at summarizing the available evidence on the topic.

RECENT FINDINGS

There are two clinical forms, isolated hyperlipidemia(a) [HyperLp(a)] with acceptable LDL-C levels (< 70 mg/dL), and combined elevation of Lp(a) and LDL-C in plasma. To date, no drugs that selectively decrease Lp(a) are available. Some novel lipid-lowering drugs can lower Lp(a) levels, but to a limited extent, as their main effect is aimed at decreasing LDL-C levels. Significant Lp(a) lowering effects were obtained with nicotinic acid at high doses. However, adverse effects apart, nicotinic acid is no longer prescribed and available in Europe for clinical use, after European Agency of Medicines (EMA) ban. The only effective therapeutic option for now is Lipoprotein Apheresis (LA), albeit with some limitations. Lastly, it is to be acknowledged that the body of evidence confirming that reducing plasma isolated elevation of Lp(a) brings cardiovascular benefit is still insufficient. However, the growing bulk of clinical, genetic, mechanistic, and epidemiological available evidence strongly suggests that Lp(a) is likely to be the smoking gun.

摘要

目的综述

大量的遗传和流行病学研究数据强烈支持脂蛋白(a) [Lp(a)]水平升高与动脉粥样硬化和心血管疾病发展之间存在因果关系。这种关系是连续的,与 Lp(a) 阈值无关,且独立于低密度脂蛋白(LDL)和高密度脂蛋白(HDL)胆固醇水平。不幸的是,Lp(a)促进动脉粥样硬化的机制尚不清楚。提出的假说包括:Lp(a)相关胆固醇在动脉内膜中的蓄积增加,随后炎症细胞募集,促炎氧化磷脂异常上传,纤溶酶原激活抑制导致纤溶受损,以及组织因子途径抑制剂抑制导致凝血增强。本文旨在总结该主题的现有证据。

最新发现

存在两种临床形式,即孤立性高脂血症(a) [HyperLp(a)],LDL-C 水平可接受(<70mg/dL),以及血浆中 Lp(a) 和 LDL-C 同时升高。迄今为止,尚无专门降低 Lp(a)的药物。一些新型降脂药物可以降低 Lp(a)水平,但程度有限,因为其主要作用是降低 LDL-C 水平。高剂量烟酸可显著降低 Lp(a)水平。然而,除了不良反应外,烟酸在欧洲已被欧洲药品管理局(EMA)禁止用于临床,不再被开处方和使用。目前唯一有效的治疗选择是脂蛋白吸附(LA),尽管存在一些局限性。最后,需要承认的是,确认降低血浆中孤立性 Lp(a)升高可带来心血管获益的证据仍然不足。然而,越来越多的临床、遗传、机制和流行病学证据强烈表明,Lp(a)很可能是罪魁祸首。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验